专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2016531145A 口腔粘膜炎の処置における使用のための新規ペプチド及び類似体审中-公开
标题翻译：新的肽及其类似物在口腔粘膜炎的治疗
公开(公告)号：JP2016531145A
公开(公告)日：2016-10-06
申请号：JP2016541974
申请日：2014-08-11
申请人：ソリジェニックスインコーポレーテッド , ソリジェニックスインコーポレーテッド , ドニーニ, オレオラDONINI, Oreola , ドニーニ, オレオラDONINI, Oreola , ローゼック, アネットROZEK, Annett , ローゼック, アネットROZEK, Annett , リー, ジャクソンLEE, Jackson , リー, ジャクソンLEE, Jackson , ノース, ジョンNORTH, John , ノース, ジョンNORTH, John , エイブラムス, マイケルABRAMS, Michael , エイブラムス, マイケルABRAMS, Michael
发明人：オレオラドニーニ， , オレオラドニーニ， , アネットローゼック， , アネットローゼック， , ジャクソンリー， , ジャクソンリー， , ジョンノース， , ジョンノース， , マイケルエイブラムス， , マイケルエイブラムス，
IPC分类号： A61K38/00 , A61K31/573 , A61P1/02 , A61P29/00 , A61P31/04 , C07K7/02
CPC分类号： C07K7/06 , A61K31/573 , A61K38/08 , A61K45/06 , C07K5/1019
摘要：化学療法誘導性粘膜炎、放射線誘導性粘膜炎、好中球減少性の感染症および口腔粘膜炎のモデルで得られた前臨床データは先天的防御レギュレータ(IDR)ペプチドの有望な指標を示す。粘膜炎のマウスおよびハムスターモデルにおいてIDRを用いて得られた前臨床有効性結果は、3日毎に投与方法が、化学療法や放射線曝露期間に依存して、7〜14回用量で粘膜炎の「ウインドウ」をカバーすることができることを示す。また、IDRはまた化学療法および/または放射線の損傷に対する先天性免疫応答と一致して、化学療法誘導性の口腔及び胃腸粘膜炎のマウスモデルにおいて有効性を示した。IDRはまた、細菌負荷を減少させるのに有効であり、さまざまなマウス感染モデルにおいて抗生物質処置の存在下または非存在下で生存率を改善した。
摘要翻译：化疗诱导的粘膜炎，辐射诱发的粘膜炎，中性粒细胞减少感染和口腔粘膜炎的模型获得的临床前数据表示先天防御调节器（IDR）肽的一个有希望的指示。临床疗效结果与IDR在粘膜炎小鼠和仓鼠模型中获得之前，施用每三天，这取决于化学疗法或放射曝光期间，粘膜炎7-14剂量“ 这表明，它可能覆盖的窗口“。此外，IDR也与化疗和/或辐射的损伤先天免疫应答相一致，在化疗诱导的口服和胃肠道粘膜炎的小鼠模型中已显示出功效。 IDR也可有效地减少在各种小鼠感染模型的存在或不存在的抗生素治疗的细菌负荷，并提高了存活。

2. 发明专利

JP2019142910A 口腔粘膜炎の処置における使用のための新規ペプチド及び類似体审中-公开
公开(公告)号：JP2019142910A
公开(公告)日：2019-08-29
申请号：JP2019075940
申请日：2019-04-11
申请人：ソリジェニックスインコーポレーテッド , ドニーニ, オレオラ , DONINI, Oreola , ローゼック, アネット , ROZEK, Annett , リー, ジャクソン , LEE, Jackson , ノース, ジョン , NORTH, John , エイブラムス, マイケル , ABRAMS, Michael
发明人：ドニーニ, オレオラ , ローゼック, アネット , リー, ジャクソン , ノース, ジョン , エイブラムス, マイケル
IPC分类号： A61P1/02 , A61P43/00 , A61P1/04 , A61P29/00 , A61K38/08 , A61K38/12 , A61K45/00 , A61K38/07
摘要：【課題】放射線療法若しくは化学療法による抗癌療法によって罹患する口腔粘膜炎等の粘膜炎又は大腸炎の発生率、重症度及び/又は罹患期間を低下又は短縮するための新規方法の提供。【解決手段】必須の構成アミノ酸としてプロリンを含有する特定の直鎖状若しくは環状のテトラペプチド又はペンタペプチドを投与する工程を含む、有害量の放射又は化学療法剤に暴露された個体の口腔粘膜炎の発生率、重症度及び/又は罹患期間を減じるための処置方法。【選択図】なし

4. 发明公开

EP3044229A4 NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF ORAL MUCOSITIS 有权
标题翻译：阿拉伯联合酋长国中性粒细胞巨细胞病毒
公开(公告)号：EP3044229A4
公开(公告)日：2017-04-19
申请号：EP14844276
申请日：2014-08-11
申请人： SOLIGENIX INC , DONINI OREOLA , ROZEK ANNETT , LEE JACKSON , NORTH JOHN , ABRAMS MICHAEL J
发明人： DONINI OREOLA , ROZEK ANNETT , LEE JACKSON , NORTH JOHN , ABRAMS MICHAEL
IPC分类号： C07K7/00 , A61K38/08 , A61P31/04 , A61P43/00
CPC分类号： C07K7/06 , A61K31/573 , A61K38/08 , A61K45/06 , C07K5/1019
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
摘要翻译：化疗引起的粘膜炎，辐射诱导的粘膜炎，中性粒细胞减少性感染和结肠炎模型中获得的临床前数据表明口腔粘膜炎是先天性防御调节剂（IDR）肽的有前途的指标。 IDRs在小鼠和仓鼠模型粘膜炎中获得的临床前效力结果表明，每3天给药应能够以7至14次剂量覆盖粘膜炎“窗口”，这取决于化疗或放射线暴露的持续时间。 IDRs还显示了化疗引起的口腔和胃肠粘膜炎的小鼠模型的功效，与先天免疫应答对化学疗法和/或辐射损伤的反应一致。 IDRs在各种鼠感染模型中，在存在或不存在抗生素治疗的同时，也有效减少细菌负担并改善存活。

5. 发明公开

EP3044229A1 NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF ORAL MUCOSITIS 有权
标题翻译：新型肽及其类似物口服粘膜炎的治疗
公开(公告)号：EP3044229A1
公开(公告)日：2016-07-20
申请号：EP14844276.7
申请日：2014-08-11
申请人： Soligenix, Inc. , Donini, Oreola , Rozek, Annett , Lee, Jackson , North, John , Abrams, Michael J.
发明人： DONINI, Oreola , ROZEK, Annett , LEE, Jackson , NORTH, John , ABRAMS, Michael
IPC分类号： C07K7/00
CPC分类号： C07K7/06 , A61K31/573 , A61K38/08 , A61K45/06 , C07K5/1019
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

6. 发明专利

GB2597879A Jig with slot template 未知
公开(公告)号：GB2597879A
公开(公告)日：2022-02-09
申请号：GB202116438
申请日：2016-10-06
申请人： LEE JACKSON
发明人： LEE JACKSON
IPC分类号： B25H3/06 , B23B47/28 , B25B11/02
摘要： A jig for use in cutting a work piece, is provided along with a method of use thereof. The jig comprises at least one slot template 102, comprising: a first end defining area, arranged such that cutting a slot using the slot template provides a first end 102, toward the joining edge of the work piece; a first engagement portion defining area 104, arranged such that cutting a slot using the slot template provides an engagement portion to receive and engage a fastening assembly (80, figure 10) , and an access portion defining area 106, arranged such that cutting a slot using the slot template provides an access portion away from the first end and the engagement portion suitable to permit access to a fastening assembly received in the cut slot thereby facilitating engagement of a fastening assembly with the engagement portion. Also disclosed is a method of engaging a fastening assembly with a slot formed in a work piece, and a jig for cutting an edge on a work piece and a complementary edge on a second work piece, and a fastening assembly comprising a threaded bolt, a nut and a washer.

7. 发明专利

AU2018214160B2 NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF ORAL MUCOSITIS 未知
公开(公告)号：AU2018214160B2
公开(公告)日：2020-07-02
申请号：AU2018214160
申请日：2018-08-13
申请人： ABRAMS MICHAEL , DONINI OREOLA , LEE JACKSON , NORTH JOHN , ROZEK ANNETT , SOLIGENIX INC
发明人： DONINI OREOLA , NORTH JOHN , ROZEK ANNETT , LEE JACKSON , ABRAMS MICHAEL
IPC分类号： C07K7/00
摘要： Abstract Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis "window" with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and / or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

8. 发明专利

SG11201601891XA NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF ORAL MUCOSITIS 未知
公开(公告)号：SG11201601891XA
公开(公告)日：2016-04-28
申请号：SG11201601891X
申请日：2014-08-11
申请人： SOLIGENIX INC , DONINI OREOLA , ROZEK ANNETT , LEE JACKSON , NORTH JOHN , ABRAMS MICHAEL
发明人： DONINI OREOLA , ROZEK ANNETT , LEE JACKSON , NORTH JOHN , ABRAMS MICHAEL
IPC分类号： C07K7/00
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

9. 发明专利

CA2923553A1 NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF ORAL MUCOSITIS 未知
公开(公告)号：CA2923553A1
公开(公告)日：2015-03-19
申请号：CA2923553
申请日：2014-08-11
申请人： SOLIGENIX INC , DONINI OREOLA , ROZEK ANNETT , LEE JACKSON , NORTH JOHN , ABRAMS MICHAEL
发明人： DONINI OREOLA , ROZEK ANNETT , LEE JACKSON , NORTH JOHN , ABRAMS MICHAEL , LEE JACKSON , LEE JACKSON , NORTH JOHN , ABRAMS MICHAEL
IPC分类号： C07K7/00
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and coiitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis "window" with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and / or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

10. 发明专利

CA54603A ANKLE BRACE FOR SKATES 未知
公开(公告)号：CA54603A
公开(公告)日：1897-01-15
申请号：CA54603D
申请日：1896-12-17
申请人： LEE JACKSON CHARLES
发明人： LEE JACKSON CHARLES

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式